Table 3.

Univariable and multivariable Cox regression analyses with robust estimator of overall survival and recurrence-free survival after curative resection of solitary HBV-related hepatocellular carcinoma in the propensity matched cohort.

	Overall survival				Recurrence-free survival
Factors	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)
Gender (male/female)	.049	0.586 (0.345–0.997)	.400		.662
Age (>60 vs ≤60, Month)	.058				.109
Total Bilirubin, umol/L	.718				.338
ALT, IU/L	.940				.159
Albumin, g/L	.764				.771
ΔNLR (>0 vs ≤0)	.006	0.622 (0.445–0.871)	.024	0.678 (0.483–0.950)	.022	0.700 (0.515–0.951)	.050	0.736 (0.541–1.000)
Differentiation (Low, Moderate, High)	.001	0.420 (0.254–0.694)	.103		.007	0.523 (0.325–0.840)	.002	0.467 (0.287–0.761)
MVI (Yes vs No)	<.001	3.730 (2.242–6.208)	<.001	5.445 (2.842–10.012)	.004	2.218 (1.295–3.799)	.018	2.043 (1.130–3.692)
Tumor Size (<5 vs ≥5, cm)	.237				.455
Cirrhosis (Yes vs No)	.059				.769
AFP (≤400 vs >400, ng/mL)	<.001	2.448 (1.498–4.001)	.012	2.036 (1.168–3.548)	<.001	2.637 (1.649–4.217)	<.001	2.610 (1.575–4.326)
HBeAg (Positive vs Negative))	.389				.407
HBV-DNA (≥2 × 103 vs 2 × <103, IU/mL)	.136				.007	0.506 (0.307–0.834)	.208
Antiviral Therapy (NtA vs NsA)	.043	0.722 (0.217–0.996)	.045	0.859 (0.531–0.907)	.028	0.373 (0.307–0.698)	.041	0.768 (0.536–0.979)
Transfusion (Yes vs No)	.394				.665
Complication (Yes vs No)	.343				.136
Immunotherapy (none Tα1 vs Tα1)	.018	0.542 (0.324–0.908)	<.001	0.308 (0.175–0.541)	.006	0.517 (0.317–0.842)	<.001	0.381 (0.229–0.633)